Motohiro Kato
Pre-Clinical Research Department
Chugai Pharmaceutical Co.
Ltd., 1-135 Komakado
Gotemba
Japan
Name/email consistency: high
- Quantitative prediction of mechanism-based inhibition caused by mibefradil in rats. Sekiguchi, N., Kato, M., Takada, M., Watanabe, H., Takata, S., Mitsui, T., Aso, Y., Ishigai, M. Drug Metab. Dispos. (2011)
- The quantitative prediction of CYP-mediated drug interaction by physiologically based pharmacokinetic modeling. Kato, M., Shitara, Y., Sato, H., Yoshisue, K., Hirano, M., Ikeda, T., Sugiyama, Y. Pharm. Res. (2008)
- Intestinal first-pass metabolism of CYP3A4 substrates. Kato, M. Drug Metab. Pharmacokinet. (2008)
- The quantitative prediction of in vivo enzyme-induction caused by drug exposure from in vitro information on human hepatocytes. Kato, M., Chiba, K., Horikawa, M., Sugiyama, Y. Drug Metab. Pharmacokinet. (2005)
- Evaluation of methods for predicting drug-drug interactions by Monte Carlo simulation. Kato, M., Tachibana, T., Ito, K., Sugiyama, Y. Drug Metab. Pharmacokinet. (2003)
- The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature. Kato, M., Chiba, K., Hisaka, A., Ishigami, M., Kayama, M., Mizuno, N., Nagata, Y., Takakuwa, S., Tsukamoto, Y., Ueda, K., Kusuhara, H., Ito, K., Sugiyama, Y. Drug Metab. Pharmacokinet. (2003)
- Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in rats. Kato, M., Okano, K., Sakamoto, Y., Miura, K., Uchimura, T., Saito, K. Arzneimittelforschung (2001)









